Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMPH
Strong BuyFull HouseAmphastar Pharmaceuticals, Inc. · Healthcare · United States · $936M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets injectable, intranasal, and inhalation products, focusing on complex generics and proprietary drugs. The company's competitive advantage lies in its expertise with difficult-to-manufacture sterile products and a robust pipeline of both generic and branded pharmaceuticals. It leverages a vertically integrated structure to control critical raw material supply and manufacturing processes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 499.0M | 644.4M | 732.0M | 719.9M | 13.0% | 730.0M | 747.7M | 784.4M | 4.4% |
| EPS | 1.88 | 2.85 | 3.29 | 2.10 | 3.8% | 1.69 | 1.92 | 2.34 | 5.5% |
| Shares | 48.1M | 48.1M | 47.6M | 45.6M | -5.1% | 42.5M | — | — | — |
| Debt | 102.6M | 623.6M | 650.5M | 656.0M | 85.6% | 688.3M | — | — | — |
| Equity | 528.7M | 639.4M | 732.3M | 788.8M | 14.3% | — | — | — | — |
| Op CF | 89.2M | 183.5M | 213.4M | 156.1M | 20.5% | 184.6M | — | — | — |
| Inv CF | -32.8M | -649.1M | -124.9M | -70.3M | — | — | — | — | — |
| Fin CF | -26.4M | 454.1M | -81.0M | -67.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMPH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc.(you) | $936M | 95 | Strong Buy |
| IRWD | Ironwood Pharmaceuticals, Inc. | $682M | 100 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| COLL | Collegium Pharmaceutical, Inc. | $786M | 72 | Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.3%